基于模型的药物开发应用和机会在mRNA-LNP治疗中
Jiawei Zhou1, Rohit Rao2, Monica E Shapiro2
1Pfizer Inc, Groton, Connecticut, USA.
Clinical pharmacology and therapeutics
|March 14, 2025
概括
模型信息化药物开发 (MIDD) 通过整合安全性和有效性评估数据来帮助mRNA-LNP疗法. 这种方法通过利用各种建模技术和跨治疗模式的知识共享来增强临床开发.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 生物技术是生物技术.
- 计算生物学 计算生物学
背景情况:
- 脂纳米粒子 (LNP) 封装mRNA已经改变了疫苗开发,包括COVID-19和癌症.
- 由于复杂的机制和有限的临床数据,mRNA-LNP疗法的临床进展受到阻碍.
- 模型信息化药物开发 (MIDD) 为应对这些挑战提供了一个框架.
研究的目的:
- 通过使用体内数据,审查MIDD在mRNA-LNP治疗药物的临床开发中的当前应用.
- 为了比较mRNA,小干扰RNA和基于腺相关病毒的基因治疗的临床药理学.
- 探索这些治疗类别之间MIDD策略的潜在知识共享.
主要方法:
- 审查各种建模和模拟技术,包括定量系统药理学 (QSP),生理学基础的药理动力学 (PBPK) 和机械/人群药理动力学/药理动力学 (PK/PD).
- 还讨论了基于模型的元分析 (MBMA).
- 对不同基于核酸的治疗方法的临床药理和MIDD应用进行比较分析.
主要成果:
- MIDD整合了各种数据来评估整个开发生命周期的安全性和有效性.
- 像QSP,PBPK和PK/PD这样的特定建模方法适用于mRNA-LNP疗法.
- 在基于mRNA,siRNA和AAV的疗法中,MIDD知识的协同应用存在潜力.
结论:
- MIDD是推动mRNA-LNP治疗开发的关键工具.
- 应用MIDD可以提高对这些复杂疗法的安全性和疗效的评估.
- 对于利益相关者来说,认识到MIDD的价值对于优化临床进展至关重要.
相关概念视频
Ribosome Profiling
3.2K
Ribosome profiling or ribo-sequencing is a deep sequencing technique that produces a snapshot of active translation in a cell. It selectively sequences the mRNAs protected by ribosomes to get an insight into a cell’s translation landscape at any given point in time.
Applications of ribosome profiling
Ribosome profiling has many applications, including in vivo monitoring of translation inside a particular organ or tissue type and quantifying new protein synthesis levels.
The technique...
Applications of ribosome profiling
Ribosome profiling has many applications, including in vivo monitoring of translation inside a particular organ or tissue type and quantifying new protein synthesis levels.
The technique...
3.2K
Pharmacogenomics: Identification of New Drug Targets
129
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Microorganisms in Medicine and Therapeutics
1.4K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.4K


